14,14,14-Trifluoro-3,6,9,12-tetraoxatetradecan-1-ol

Catalog No.: 
ACARIB253
CAS No.: 
1807512-41-9
Molecular Formula: 
C10H19F3O5
Molecular Weight: 
276.25
14,14,14-Trifluoro-3,6,9,12-tetraoxatetradecan-1-ol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$67.00In stockInquiry
100mg98%$110.00In stockInquiry
250mg98%$202.00In stockInquiry
1g98%$524.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name14,14,14-Trifluoro-3,6,9,12-tetraoxatetradecan-1-ol
IUPAC Name14,14,14-trifluoro-3,6,9,12-tetraoxatetradecan-1-ol
MDL No.MFCD28950755
Molecular FormulaC10H19F3O5
Molecular Weight276.25
SMILESOCCOCCOCCOCCOCC(F)(F)F
InChI KeyWRLCZARSFIXUQS-UHFFFAOYSA-N
Synonym1,1,1-Trifluoroethyl-PEG5-Alcohol;1,1,1-Trifluoroethyl-PEG4-alcohol;3,6,9,12-Tetraoxatetradecan-1-ol, 14,14,14-trifluoro-;14,14,14-trifluoro-3,6,9,12-tetraoxatetradecan-1-ol
CAS No.1807512-41-9
PubChem CID91809449

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACARIB253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACARIB253 route product structure diagram
    ACARIB2531807512-41-9In Stock
Inquiry

2. ACARIB253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACARIB253 route product structure diagram
    ACARIB2531807512-41-9In Stock
Inquiry

3. ACARIB253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACARIB253 route product structure diagram
    ACARIB2531807512-41-9In Stock
Inquiry

Comments (0)